Sally C. Pipes
Commentary
Obamacare Vulnerable to a Real Fraud Problem
The Centers for Medicare and Medicaid Services says it canceled the policies only after investigating and confirming that the enrollments were unauthorized. Many involved people enrolled without their knowledge, sometimes by dishonest insurance agents and brokers. Those cancellations are expected to return roughly $2.2 billion in taxpayer-funded subsidies. And there’s ...
Commentary
Medicare for All comes with a human cost voters don’t realize
“Medicare for All” is enjoying a political resurgence. A KFF poll released last week found that two-thirds of Americans support a national health plan — the highest level since the organization began asking about the idea in 2017. But enthusiasm falls when Americans confront some of the trade-offs. Just 24% ...
Commentary
The FDA Is Struggling To Police The Peptide Boom
Unlike FDA-approved peptide medicines, many compounds marketed online have never undergone rigorous clinical testing or regulatory review. That leaves fundamental questions about their safety and effectiveness unanswered. The bigger challenge is the supply chain. Overseas manufacturers can profit from American demand while making it difficult for U.S. authorities to enforce ...
Commentary
The $3.3 Trillion Case For Bayh-Dole
The federal government once held roughly 28,000 patents on inventions arising from taxpayer-supported research. Almost none of them went anywhere. By 1980, the government had managed to license fewer than 5% of them. Then Congress changed the rules. The Bayh-Dole Act of 1980 allowed universities, nonprofits, and small businesses to ...
Commentary
Medicare for All – Careful of What You Ask For
Medicare for All is back on Democrats’ legislative menu. It was featured on the lengthy list of healthcare policy options a House Democratic working group recently sent Minority Leader Rep. Hakeem Jeffries, D-N.Y. Rep. Pramila Jayapal, D-Wash., the lead House sponsor of Medicare for All, has made clear her plans ...
Commentary
Want cheaper health insurance? Don’t kill HSAs
A new study from Georgetown University offers a three-part strategy for cutting health insurance costs — a worthwhile goal if there ever was one. Remarkably, the plan would effectively eliminate one of the most powerful tools for constraining health spending and saving patients money — health savings accounts, or HSAs. ...
Commentary
Consumer Choice Should Apply to Hospitals as Well
Americans are clamoring for relief from soaring healthcare prices. Thankfully, Congress seems to be looking in the right place for the answer. Last week, members of a House Judiciary subcommittee heard testimony on “the effect of mergers, certificate of need laws, regulations, vertical integration, and fraudulent insurance practices on healthcare ...
California
What California’s Healthcare Spending Doesn’t Guarantee | Sally Pipes
Watch as PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally Pipes examines what she would change about how healthcare is paid for in the United States and which parts of the system she believes should be preserved. Patients in California can enter a hospital without ...
Commentary
The GLP-1 Shortage Is Over. Mass-Market Compounding Should Be, Too
The U.S. Food and Drug Administration’s effort to rein in mass-market copies of blockbuster GLP-1 drugs just survived a major legal challenge. Last month, the U.S. Court of Appeals for the Fifth Circuit upheld the agency’s determination that the shortage of semaglutide—the active ingredient in Ozempic and Wegovy—is over. In ...
Commentary
The first mRNA flu vaccine may be just the beginning
Flu season is coming. And for the first time, Americans will have an mRNA vaccine to help fight it. Last month, the Food and Drug Administration approved Moderna’s mFLUSIVA for adults 50 and older. In a large Phase 3 trial, the vaccine was almost 27% more effective than a standard ...
Obamacare Vulnerable to a Real Fraud Problem
The Centers for Medicare and Medicaid Services says it canceled the policies only after investigating and confirming that the enrollments were unauthorized. Many involved people enrolled without their knowledge, sometimes by dishonest insurance agents and brokers. Those cancellations are expected to return roughly $2.2 billion in taxpayer-funded subsidies. And there’s ...
Medicare for All comes with a human cost voters don’t realize
“Medicare for All” is enjoying a political resurgence. A KFF poll released last week found that two-thirds of Americans support a national health plan — the highest level since the organization began asking about the idea in 2017. But enthusiasm falls when Americans confront some of the trade-offs. Just 24% ...
The FDA Is Struggling To Police The Peptide Boom
Unlike FDA-approved peptide medicines, many compounds marketed online have never undergone rigorous clinical testing or regulatory review. That leaves fundamental questions about their safety and effectiveness unanswered. The bigger challenge is the supply chain. Overseas manufacturers can profit from American demand while making it difficult for U.S. authorities to enforce ...
The $3.3 Trillion Case For Bayh-Dole
The federal government once held roughly 28,000 patents on inventions arising from taxpayer-supported research. Almost none of them went anywhere. By 1980, the government had managed to license fewer than 5% of them. Then Congress changed the rules. The Bayh-Dole Act of 1980 allowed universities, nonprofits, and small businesses to ...
Medicare for All – Careful of What You Ask For
Medicare for All is back on Democrats’ legislative menu. It was featured on the lengthy list of healthcare policy options a House Democratic working group recently sent Minority Leader Rep. Hakeem Jeffries, D-N.Y. Rep. Pramila Jayapal, D-Wash., the lead House sponsor of Medicare for All, has made clear her plans ...
Want cheaper health insurance? Don’t kill HSAs
A new study from Georgetown University offers a three-part strategy for cutting health insurance costs — a worthwhile goal if there ever was one. Remarkably, the plan would effectively eliminate one of the most powerful tools for constraining health spending and saving patients money — health savings accounts, or HSAs. ...
Consumer Choice Should Apply to Hospitals as Well
Americans are clamoring for relief from soaring healthcare prices. Thankfully, Congress seems to be looking in the right place for the answer. Last week, members of a House Judiciary subcommittee heard testimony on “the effect of mergers, certificate of need laws, regulations, vertical integration, and fraudulent insurance practices on healthcare ...
What California’s Healthcare Spending Doesn’t Guarantee | Sally Pipes
Watch as PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally Pipes examines what she would change about how healthcare is paid for in the United States and which parts of the system she believes should be preserved. Patients in California can enter a hospital without ...
The GLP-1 Shortage Is Over. Mass-Market Compounding Should Be, Too
The U.S. Food and Drug Administration’s effort to rein in mass-market copies of blockbuster GLP-1 drugs just survived a major legal challenge. Last month, the U.S. Court of Appeals for the Fifth Circuit upheld the agency’s determination that the shortage of semaglutide—the active ingredient in Ozempic and Wegovy—is over. In ...
The first mRNA flu vaccine may be just the beginning
Flu season is coming. And for the first time, Americans will have an mRNA vaccine to help fight it. Last month, the Food and Drug Administration approved Moderna’s mFLUSIVA for adults 50 and older. In a large Phase 3 trial, the vaccine was almost 27% more effective than a standard ...